Sorrento Therapeutics (SRNE) stock Forecast for 2022 – 2026
Last update: November 26, 2022 (17:55)Sector: Healthcare
The share price of Sorrento Therapeutics, Inc. (SRNE) now
What analysts predict: $12
52-week high/low: $6.53 / $1.15
50/200 Day Moving Average: $1.599 / $2.037
This figure corresponds to the average price over the previous 50/200 days. For Sorrento Therapeutics stocks, the 50-day moving average is the resistance level today.
For Sorrento Therapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in Sorrento Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Sorrento Therapeutics stock price in 2022, 2023, 2024, 2025, 2026. How much will one Sorrento Therapeutics share be worth in 2022 - 2026?
When should I take profit in Sorrento Therapeutics stock? When should I record a loss on Sorrento Therapeutics stock? What are analysts' forecasts for Sorrento Therapeutics stock? What is the future of Sorrento Therapeutics stock? We forecast Sorrento Therapeutics stock performance using neural networks based on historical data on Sorrento Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Sorrento Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Sorrento Therapeutics shares. This happens once a day.
Historical and forecast chart of Sorrento Therapeutics stock
The chart below shows the historical price of Sorrento Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Sorrento Therapeutics stock price can be found in the table below.
Long-term forecasts by years.
Sorrento Therapeutics daily forecast for a month
Sorrento Therapeutics Daily Price Targets
Sorrento Therapeutics Stock Forecast 11-28-2022.
Forecast target price for 11-28-2022: $1.34.
Negative dynamics for Sorrento Therapeutics shares will prevail with possible volatility of 7.685%.
Pessimistic target level: 1.28
Optimistic target level: 1.39
Sorrento Therapeutics Stock Forecast 11-29-2022.
Forecast target price for 11-29-2022: $1.33.
Negative dynamics for Sorrento Therapeutics shares will prevail with possible volatility of 6.320%.
Pessimistic target level: 1.27
Optimistic target level: 1.36
Sorrento Therapeutics Stock Forecast 11-30-2022.
Forecast target price for 11-30-2022: $1.33.
Positive dynamics for Sorrento Therapeutics shares will prevail with possible volatility of 4.031%.
Pessimistic target level: 1.31
Optimistic target level: 1.36
Sorrento Therapeutics Stock Forecast 12-01-2022.
Forecast target price for 12-01-2022: $1.29.
Negative dynamics for Sorrento Therapeutics shares will prevail with possible volatility of 5.260%.
Pessimistic target level: 1.24
Optimistic target level: 1.31
Sorrento Therapeutics Stock Forecast 12-02-2022.
Forecast target price for 12-02-2022: $1.33.
Positive dynamics for Sorrento Therapeutics shares will prevail with possible volatility of 5.045%.
Pessimistic target level: 1.29
Optimistic target level: 1.36
Sorrento Therapeutics Stock Forecast 12-03-2022.
Forecast target price for 12-03-2022: $1.40.
Positive dynamics for Sorrento Therapeutics shares will prevail with possible volatility of 6.046%.
Pessimistic target level: 1.37
Optimistic target level: 1.46
SRNE (SRNE) Monthly Stock Prediction for 2022
Sorrento Therapeutics forecast for this year
Sorrento Therapeutics Stock Prediction for Dec 2022
An uptrend is forecast for this month with an optimal target price of $1.39468. Pessimistic: $1.24. Optimistic: $1.46
Sorrento Therapeutics (SRNE) Monthly Stock Prediction for 2023
Sorrento Therapeutics (SRNE) Monthly Stock Prediction for 2024
Sorrento Therapeutics (SRNE) Monthly Stock Prediction for 2025
Sorrento Therapeutics (SRNE) Monthly Stock Prediction for 2026
Sorrento Therapeutics information and performance
Sorrento Therapeutics, Inc., a clinical stage Biopharma company, develops treatments for cancer, autoimmune, inflammatory and neurodegenerative diseases. She operates in two segments – Sorrento Therapeutics and Scilex. The company provides cancer therapists through the use of a proprietary r-monoclonal antibody antibody library and targeted delivery conditions that include chimeric antigen receptor T-cell therapy (car-T), dimeric antigen receptor T-cell therapy, and antibody-drug conjugates as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biological substances directly to the lymphatic system. In addition, the company’s clinical programs include anti-CD38 CAR-T therapy for the treatment of multiple myeloma as well as amyloidosis and graft versus host diseases. In addition, he is developing resiniferatoxin, a neopioid-based TRPV1 agonist neurotoxin for the treatment of advanced cancer and osteoarthritis of knee pain; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, the company is developing SEMDEXA, an injectable viscous gel formulation that is a Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system in clinical development for chronic low back pain. She has various collaborations with SmartPharm Therapeutics Inc. to develop a gene-encoded vaccine antibody to protect against COVID-19; Celularity, Inc. to initiate a Phase I / II clinical trial with up to 86 COVID-19 patients; and the Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, and a Research Trials Agreement with the University of Texas Medical Branch at Galveston for preclinical testing of Sorrento’s COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
4955 DIRECTORS PLACE, SAN DIEGO, CA, US
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.